Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
AstraZeneca PLC (AZN) (Q4FY24) – Advancing growth, innovation, and market resilience
$240.00
AZN’s revenue grew 25% in Q4 2024, pushing full-year growth to 21%, surpassing forecasts.
Description
Description
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
In the US sales grew by 28% in Q4FY24 to $6.5bn from $5.10bn in Q4FY23, whereas in FY24 sales grew by 21.8% to $23.23bn from $19.07bn in the same period last year.
AstraZeneca in the last 3 months the stock has given a return of 12%, and the stock price increased to $73.92 as of Apr 03, 2025, from $66.25 as of Jan 03, 2025.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/adidas-equity-report-q3-24/
